Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from 4basebio UK Societas ( (GB:4BB) ) is now available.
4basebio PLC reported significant growth in 2024, doubling its DNA sales revenue and securing a £40 million equity investment to support its expansion plans. The company achieved several milestones, including supplying synthetic DNA for vaccine trials, obtaining a GMP manufacturing license, and forming a Strategic Advisory Board. These developments position 4basebio as a leader in the synthetic DNA market, with expectations of continued revenue growth and innovation in 2025.
The most recent analyst rating on (GB:4BB) stock is a Buy with a £1600.00 price target. To see the full list of analyst forecasts on 4basebio UK Societas stock, see the GB:4BB Stock Forecast page.
More about 4basebio UK Societas
4basebio PLC is a Cambridge, UK-based life sciences service company, known for its development, manufacture, and commercialization of synthetic DNA and non-viral delivery systems. It focuses on cell and gene therapy and vaccine markets, offering products that provide application-specific benefits and quicker manufacturing times compared to plasmid DNA. The company operates in the UK and Spain, with a strong emphasis on research and development to expand its product offerings.
Average Trading Volume: 947
Technical Sentiment Signal: Hold
Current Market Cap: £174.1M
See more data about 4BB stock on TipRanks’ Stock Analysis page.